Idiopathic Parkinson's Disease Clinical Trial
Official title:
Does Home-based Treadmill Training Improve Walking Capacity and Quality of Life in People With Early to Mid-stage Parkinson's Disease?
The major aim of this study is to determine the efficacy of a home-based treadmill walking program in improving walking capacity and quality of life in people with early mid-stage Parkinson's disease(PD).
After Alzheimer's disease, Parkinson's disease (PD) is the most common degenerative
neurological condition suffered by Australians, with more than 30,000 Australians having PD
at any one time (Parkinson's Australia). Hypokinesia, ie, reduced speed and amplitude of
movement, is a major impairment of motor control affecting walking in people with PD. Over
time, the development of slow, shuffling walking contributes to loss of independence and
falls, with devastating consequences for individuals with PD and their families(Ashburn et
al, 2001, Playfer 2001). Any decrease or delay in disability will reduce the personal and
financial costs to individuals with PD, their families, health care resources and the
community.
A number of previous studies suggest exercise capacity and exercise habits are positively
correlated. In people with mild Parkinson's disease (Canning et al 2005), walking capacity,
measured as distance walked in the 6-min walk test, correlated with the amount of walking
(r=.64, p<0.01) performed each week. Similarly, in an earlier study of people with mild to
moderate Parkinson's disease, regular exercise was associated with better exercise capacity
(Canning et al 1997). It appears, therefore, that proactive intervention aimed at developing
good exercise habits in sedentary individuals with early to mid-stage Parkinson's disease
has the potential to reduce or delay walking difficulties.
This study aims to establish the efficacy of a home-based treadmill walking program in
providing an early intervention which addresses the primary motor control impairment of
hypokinesia, while at the same time maintaining or improving exercise capacity.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03665493 -
Dopamine Effect on Inhibitory Control
|
N/A | |
Completed |
NCT02227355 -
Evaluating the Effectiveness of Neupro® (Rotigotine) and L-dopa Combination Therapy in Patients With Parkinson's Disease
|
N/A | |
Completed |
NCT01026428 -
A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics
|
Phase 1/Phase 2 | |
Completed |
NCT00664157 -
Facial Expression Recognition of Emotion and Categorization of Emotional Words in Parkinson's Disease. Impact of L-Dopa and Deep Brain Stimulation of Subthalamic Nucleus
|
N/A | |
Completed |
NCT04524143 -
The Acute Effect of Cervical Mobilization in Parkinson's Disease
|
N/A | |
Completed |
NCT05107531 -
Investigation of Gait, Foot Pressure Distribution and Balance in Parkinson's Patients With Motor Freezing
|
||
Completed |
NCT04524182 -
The Acute Effect of Lumbosacral Mobilization in Parkinson's Disease
|
N/A | |
Completed |
NCT00985517 -
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT01968031 -
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
|
Phase 3 | |
Completed |
NCT01970813 -
Efficacy of Acupuncture and Bee Venom Acupuncture on Patients With Idiopathic Parkinson's Disease
|
N/A | |
Completed |
NCT01221948 -
Vercise Implantable Stimulator for Treating Parkinson's Disease
|
Phase 2 | |
Terminated |
NCT01028586 -
MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)
|
Phase 3 | |
Completed |
NCT00239564 -
Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02240030 -
Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
|
Phase 3 | |
Completed |
NCT00605683 -
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
|
Phase 3 | |
Completed |
NCT00400634 -
Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease
|
Phase 2 | |
Completed |
NCT01227265 -
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)
|
Phase 3 | |
Completed |
NCT02565628 -
PF-06669571 In Subjects With Idiopathic Parkinson's Disease
|
Phase 1 | |
Completed |
NCT01617135 -
Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes
|
Phase 2 | |
Completed |
NCT01606670 -
Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Disease
|